Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

In Reply to Zhang.

Parikh RR, Grossbard ML, Harrison LB, Yahalom J.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):501. doi: 10.1016/j.ijrobp.2017.04.038. No abstract available.

PMID:
28872005
2.

Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.

Becker DJ, Wisnivesky JP, Grossbard ML, Chachoua A, Camidge DR, Levy BP.

Clin Lung Cancer. 2017 Jan;18(1):e35-e40. doi: 10.1016/j.cllc.2016.08.008. Epub 2016 Oct 5.

PMID:
28029530
3.

Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma.

Parikh RR, Grossbard ML, Harrison LB, Yahalom J.

Radiother Oncol. 2016 Jan;118(1):52-9. doi: 10.1016/j.radonc.2015.10.022. Epub 2015 Oct 29.

PMID:
26522061
4.

Impact of delays in definitive treatment on overall survival: a National Cancer Database study of patients with Hodgkin lymphoma.

Parikh RR, Grossbard ML, Harrison LB, Yahalom J.

Leuk Lymphoma. 2016 May;57(5):1074-82. doi: 10.3109/10428194.2015.1094696. Epub 2015 Oct 15.

PMID:
26374099
5.

Early-Stage Classic Hodgkin Lymphoma: The Utilization of Radiation Therapy and Its Impact on Overall Survival.

Parikh RR, Grossbard ML, Harrison LB, Yahalom J.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):684-93. doi: 10.1016/j.ijrobp.2015.06.039. Epub 2015 Jul 6.

PMID:
26279323
6.

Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival.

Parikh RR, Grossbard ML, Harrison LB, Yahalom J.

Leuk Lymphoma. 2016 Feb;57(2):320-327. doi: 10.3109/10428194.2015.1065978. Epub 2015 Oct 2.

7.

Disparities in survival by insurance status in patients with Hodgkin lymphoma.

Parikh RR, Grossbard ML, Green BL, Harrison LB, Yahalom J.

Cancer. 2015 Oct 1;121(19):3515-24. doi: 10.1002/cncr.29518. Epub 2015 Jun 8.

8.

Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy.

Parikh RR, Moskowitz BK, Maher E, Della Rocca D, Della Rocca R, Culliney B, Shapira I, Grossbard ML, Harrison LB, Hu K.

Leuk Lymphoma. 2015 May;56(5):1266-70. doi: 10.3109/10428194.2014.979415. Epub 2015 Jan 28.

PMID:
25356924
9.

Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment.

Goel A, Fan W, Patel AA, Devabhaktuni M, Grossbard ML.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):261-70. doi: 10.1016/j.clml.2014.01.006. Epub 2014 Feb 3. Review.

PMID:
24650975
10.

Impact of oncology drug shortages on patient therapy: unplanned treatment changes.

Becker DJ, Talwar S, Levy BP, Thorn M, Roitman J, Blum RH, Harrison LB, Grossbard ML.

J Oncol Pract. 2013 Jul;9(4):e122-8. doi: 10.1200/JOP.2012.000799. Epub 2013 Mar 19.

11.

Hepatosplenic γδ T-cell lymphoma: an overview.

Visnyei K, Grossbard ML, Shapira I.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):360-9. doi: 10.1016/j.clml.2013.03.011. Review.

PMID:
23876844
12.

Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.

Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS.

J Gastrointest Cancer. 2013 Jun;44(2):182-9. doi: 10.1007/s12029-012-9466-2.

PMID:
23208490
13.

Vitamin D and breast cancer.

Shao T, Klein P, Grossbard ML.

Oncologist. 2012;17(1):36-45. doi: 10.1634/theoncologist.2011-0278. Epub 2012 Jan 10. Review.

14.

Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management.

Shao T, Grossbard ML, Klein P.

Clin Breast Cancer. 2011 Dec;11(6):417-9. doi: 10.1016/j.clbc.2011.06.006. Epub 2011 Aug 10.

15.

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.

Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD; Cancer Leukemia Group B; Eastern Cooperative Oncology Group.

Leuk Lymphoma. 2011 Apr;52(4):587-96. doi: 10.3109/10428194.2010.543714. Epub 2011 Jan 28.

16.

Systemic approaches for multifocal bronchioloalveolar carcinoma: is there an appropriate target?

Levy BP, Drilon A, Makarian L, Patel AA, Grossbard ML.

Oncology (Williston Park). 2010 Sep;24(10):888-98, 900. Review.

17.

Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review.

Razaq W, Goel A, Amin A, Grossbard ML.

Clin Lymphoma Myeloma. 2009 Jun;9(3):E5-9. doi: 10.3816/CLM.2009.n.052.

PMID:
19525185
18.

Optimal response to 100 microg/kg anti-Rh(D) in two patients who had suboptimal responses to 75 microg/kg anti-Rh(D).

Varma M, Beautyman EJ, Grossbard ML.

Am J Hematol. 2009 Feb;84(2):124. doi: 10.1002/ajh.21322. No abstract available.

19.

Metastatic pancreatic cancer 2008: is the glass less empty?

Nieto J, Grossbard ML, Kozuch P.

Oncologist. 2008 May;13(5):562-76. doi: 10.1634/theoncologist.2007-0181. Review.

20.

131I tositumomab: a viewpoint by Michael L. Grossbard.

Grossbard ML.

BioDrugs. 2000 Sep;14(3):203-4. No abstract available.

PMID:
18034571
21.

Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.

Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, Kozuch P.

Anticancer Drugs. 2007 Mar;18(3):263-71.

PMID:
17264757
22.

Non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue.

Cohen SM, Petryk M, Varma M, Kozuch PS, Ames ED, Grossbard ML.

Oncologist. 2006 Nov-Dec;11(10):1100-17. Review.

23.

Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma.

Grann VR, Hershman D, Jacobson JS, Tsai WY, Wang J, McBride R, Mitra N, Grossbard ML, Neugut AI.

Cancer. 2006 Oct 1;107(7):1530-41.

24.

The role of perioperative chemotherapy in the treatment of urothelial cancer.

Cohen SM, Goel A, Phillips J, Ennis RD, Grossbard ML.

Oncologist. 2006 Jun;11(6):630-40. Review.

25.

Primary systemic therapy of breast cancer.

Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH.

Oncologist. 2006 Jun;11(6):574-89. Review.

26.

Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI.

Leuk Lymphoma. 2005 Nov;46(11):1569-73.

PMID:
16236611
27.

Bone marrow metastases from glioblastoma multiforme--A case report and review of the literature.

Rajagopalan V, El Kamar FG, Thayaparan R, Grossbard ML.

J Neurooncol. 2005 Apr;72(2):157-61. Review.

PMID:
15925996
28.

The horizon of antiangiogenic therapy for colorectal cancer.

Olszewski AJ, Grossbard ML, Kozuch PS.

Oncology (Williston Park). 2005 Mar;19(3):297-306; discussion 306, 308, 317-33. Review.

29.

Gallbladder and biliary tract carcinoma: A comprehensive update, Part 2.

Daines WP, Rajagopalan V, Grossbard ML, Kozuch P.

Oncology (Williston Park). 2004 Jul;18(8):1049-59; discussion 1060, 1065-6, 1068. Review.

30.

Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1.

Rajagopalan V, Daines WP, Grossbard ML, Kozuch P.

Oncology (Williston Park). 2004 Jun;18(7):889-96. Review.

31.

Empowering targeted therapy: lessons from rituximab.

Olszewski AJ, Grossbard ML.

Sci STKE. 2004 Jul 6;2004(241):pe30. Review.

PMID:
15252219
32.

Pancreatic carcinoma with brain metastases: case report and literature review.

El Kamar FG, Jindal K, Grossbard ML, Mizrachi HH, Kozuch PS.

Dig Liver Dis. 2004 May;36(5):355-60. Review.

PMID:
15191206
33.

Alemtuzumab in B-cell chronic lymphocytic leukemia.

Shapira I, Grossbard ML.

Clin Lymphoma. 2004 Mar;4(4):228-9. Review. No abstract available.

PMID:
15072614
35.

Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.

Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P.

Cancer Invest. 2003;21(4):489-96.

PMID:
14533437
36.

Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care.

el-Kamar FG, Grossbard ML, Kozuch PS.

Oncologist. 2003;8(1):18-34. Review.

37.

Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.

Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F.

Blood. 2002 Apr 15;99(8):2685-93.

38.

CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.

Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek AJ, Ellman L, Harmon D, Grossbard ML, Anderson KC.

J Immunother. 2002 Jan-Feb;25(1):72-81.

PMID:
11924912
39.

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R.

Wilson WH, Gutierrez M, O'Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML.

Semin Oncol. 2002 Feb;29(1 Suppl 2):41-7.

PMID:
11842388
40.

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R.

Wilson WH, Gutierrez M, O'Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML.

Semin Oncol. 2002 Feb;29(1S2):41-47. doi: 10.1053/sonc.2002.30151.

PMID:
28140091
41.

A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.

Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW.

Cancer. 2002 Jan 1;94(1):97-103.

42.

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW.

Oncologist. 2001;6(6):488-95.

43.

Rituximab therapy of B-cell neoplasms.

Petryk M, Grossbard ML.

Clin Lymphoma. 2000 Dec;1(3):186-94; discussion 195-6. Review.

PMID:
11707828
44.

The expanding frontier of radioimmunotherapy of relapsed Non-hodgkin's lymphoma.

Kozuch P, Grossbard ML.

Clin Lymphoma. 2000 Sep;1(2):158-9. No abstract available.

PMID:
11707826
45.

Hematologic malignancies.

Petryk M, Grossbard ML.

Oncologist. 2001;6(4):317-26. Review.

46.

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI.

J Clin Oncol. 2001 Jan 15;19(2):389-97.

PMID:
11208830
47.
48.

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.

Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, Soong SJ.

J Clin Oncol. 2000 Apr;18(8):1614-21.

PMID:
10764421
49.

Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens.

Treon SP, Shima Y, Grossbard ML, Preffer FI, Belch AR, Pilarski LM, Anderson KC.

Ann Oncol. 2000;11 Suppl 1:107-11. Review.

PMID:
10707790
50.

Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.

Perry MC, Ihde DC, Herndon JE 2nd, Grossbard ML, Grethein SJ, Atkins JN, Vokes EE, Green MR.

Lung Cancer. 2000 Apr;28(1):63-8.

PMID:
10704711

Supplemental Content

Loading ...
Support Center